AU2733697A - Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression - Google Patents
Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expressionInfo
- Publication number
- AU2733697A AU2733697A AU27336/97A AU2733697A AU2733697A AU 2733697 A AU2733697 A AU 2733697A AU 27336/97 A AU27336/97 A AU 27336/97A AU 2733697 A AU2733697 A AU 2733697A AU 2733697 A AU2733697 A AU 2733697A
- Authority
- AU
- Australia
- Prior art keywords
- vpf
- vegf
- expression
- growth factor
- vascular endothelial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/335—Modified T or U
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1575296P | 1996-04-17 | 1996-04-17 | |
US60015752 | 1996-04-17 | ||
PCT/US1997/006412 WO1997039120A2 (en) | 1996-04-17 | 1997-04-17 | Antisense inhibitors of vascular endothelial growth factor (vefg/vpf) expression |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU43802/01A Division AU4380201A (en) | 1996-04-17 | 2001-05-10 | Antisense inhibitors of vascular endothelial growth factor (VEgF/VPF) expression |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2733697A true AU2733697A (en) | 1997-11-07 |
Family
ID=21773402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU27336/97A Abandoned AU2733697A (en) | 1996-04-17 | 1997-04-17 | Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0910634A2 (en) |
JP (1) | JP2000509259A (en) |
KR (1) | KR20000005561A (en) |
AU (1) | AU2733697A (en) |
BR (1) | BR9708701A (en) |
CA (1) | CA2251945A1 (en) |
WO (1) | WO1997039120A2 (en) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010018514A1 (en) * | 1998-07-31 | 2001-08-30 | Mcgall Glenn H. | Nucleic acid labeling compounds |
US6965020B2 (en) | 1996-01-23 | 2005-11-15 | Affymetrix, Inc. | Nucleic acid labeling compounds |
US7468243B2 (en) | 2001-03-12 | 2008-12-23 | Affymetrix, Inc. | 2-aminopyrimidin-4-one nucleic acid labeling compounds |
US7423143B2 (en) | 1996-01-23 | 2008-09-09 | Affymetrix. Inc. | Nucleic acid labeling compounds |
US5837283A (en) | 1997-03-12 | 1998-11-17 | The Regents Of The University Of California | Cationic lipid compositions targeting angiogenic endothelial cells |
US7112338B2 (en) | 1997-03-12 | 2006-09-26 | The Regents Of The University Of California | Cationic liposome delivery of taxanes to angiogenic blood vessels |
DE69919869T2 (en) | 1998-06-10 | 2005-09-29 | Biognostik Gesellschaft für Biomolekulare Diagnostik mbH | STIMULATION OF THE IMMUNE SYSTEM |
EP0978561A1 (en) * | 1998-08-07 | 2000-02-09 | Hoechst Marion Roussel Deutschland GmbH | Antisense oligonucleotides for the inhibition of VEGF expression |
EP1252308A2 (en) * | 2000-01-19 | 2002-10-30 | Parkash S. Gill | Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
ES2336887T5 (en) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediators of RNA interference specific to RNA sequences |
EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
WO2006006948A2 (en) | 2002-11-14 | 2006-01-19 | Dharmacon, Inc. | METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY |
PT2284266E (en) * | 2002-11-14 | 2013-12-17 | Thermo Fisher Scient Biosciences Inc | Sirna targeting tp53 |
CN100371444C (en) * | 2005-12-12 | 2008-02-27 | 清华大学深圳研究生院 | VEGF expression-inhibiting siRNA and application thereof |
EP1976567B1 (en) | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
EP2370581B1 (en) | 2008-12-04 | 2016-08-03 | CuRNA, Inc. | Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf |
CN107338251A (en) | 2008-12-04 | 2017-11-10 | 库尔纳公司 | It is diseases related that natural antisense transcript by suppressing tumor suppressor gene treats tumor suppressor gene |
JP6091752B2 (en) | 2008-12-04 | 2017-03-08 | クルナ・インコーポレーテッド | Treatment of erythropoietin (EPO) -related diseases by suppression of natural antisense transcripts against EPO |
HUE026280T2 (en) | 2009-02-12 | 2016-06-28 | Curna Inc | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
JP6116242B2 (en) | 2009-03-16 | 2017-04-19 | クルナ・インコーポレーテッド | Treatment of NRF2-related diseases by suppression of natural antisense transcripts against nuclear factor (erythrocyte-derived 2) -like 2 (NRF2) |
JP5904935B2 (en) | 2009-03-17 | 2016-04-20 | クルナ・インコーポレーテッド | Treatment of DLK1-related diseases by suppression of natural antisense transcripts against Delta-like 1 homolog (DLK1) |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
CN103223177B (en) | 2009-05-06 | 2016-08-10 | 库尔纳公司 | By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene |
CA3185821A1 (en) | 2009-05-08 | 2010-11-11 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
EP2432881B1 (en) | 2009-05-18 | 2017-11-15 | CuRNA, Inc. | Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor |
KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
KR20120024819A (en) | 2009-05-28 | 2012-03-14 | 오피케이오 큐알엔에이, 엘엘씨 | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene |
KR101702689B1 (en) | 2009-06-16 | 2017-02-06 | 큐알엔에이, 인크. | Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1 |
ES2620960T3 (en) | 2009-06-16 | 2017-06-30 | Curna, Inc. | Treatment of diseases related to a collagen gene by inhibiting a natural antisense transcript to a collagen gene |
CA2765889A1 (en) | 2009-06-24 | 2010-12-29 | Opko Curna, Llc | Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2 |
KR101807324B1 (en) | 2009-06-26 | 2017-12-08 | 큐알엔에이, 인크. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
ES2585360T3 (en) | 2009-08-05 | 2016-10-05 | Curna, Inc. | Treatment of diseases related to an insulin gene (INS) by inhibition of natural antisense transcription in an insulin gene (INS) |
KR101827015B1 (en) | 2009-08-11 | 2018-02-07 | 큐알엔에이, 인크. | Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq) |
CN102482670B (en) | 2009-08-21 | 2018-06-15 | 库尔纳公司 | CHIP relevant diseases are treated by inhibiting the natural antisense transcript of ' C-terminal of HSP70- interaction proteins ' (CHIP) |
WO2011031482A2 (en) | 2009-08-25 | 2011-03-17 | Curna, Inc. | Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap |
US20120295952A1 (en) | 2009-09-25 | 2012-11-22 | Curna, Inc. | Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity |
JP6025567B2 (en) | 2009-12-16 | 2016-11-16 | カッパーアールエヌエー,インコーポレイテッド | Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1) |
WO2011079261A2 (en) | 2009-12-23 | 2011-06-30 | Curna, Inc. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
RU2619185C2 (en) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2 |
CA2785173A1 (en) | 2009-12-29 | 2011-07-28 | Curna, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
JP5982288B2 (en) | 2009-12-29 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63) |
ES2677044T3 (en) | 2009-12-31 | 2018-07-27 | Curna, Inc. | Treatment of diseases related to insulin receptor substrate 2 (IRS2) by inhibition of natural antisense transcript for IRS2 and transcription factor E3 (TFE3) |
NO2521784T3 (en) | 2010-01-04 | 2018-05-05 | ||
RU2612161C2 (en) | 2010-01-06 | 2017-03-02 | Курна, Инк. | Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to pancreatic developmental gene |
ES2664866T3 (en) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg |
CN102782135A (en) | 2010-01-25 | 2012-11-14 | 库尔纳公司 | Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1 |
KR101838308B1 (en) | 2010-02-22 | 2018-03-13 | 큐알엔에이, 인크. | Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1 |
CA2795145C (en) | 2010-04-02 | 2019-01-22 | Curna, Inc. | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
EP3517613A1 (en) | 2010-04-09 | 2019-07-31 | CuRNA, Inc. | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
US9089588B2 (en) | 2010-05-03 | 2015-07-28 | Curna, Inc. | Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to a sirtuin (SIRT) |
TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
EP2576783B1 (en) | 2010-05-26 | 2017-11-29 | CuRNA, Inc. | Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1 |
EP2576784B1 (en) | 2010-05-26 | 2017-11-15 | CuRNA, Inc. | Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra |
PT2585596T (en) | 2010-06-23 | 2021-03-23 | Curna Inc | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
NO2593547T3 (en) | 2010-07-14 | 2018-04-14 | ||
EP2598639A4 (en) | 2010-07-28 | 2014-08-13 | Alcon Res Ltd | Sirna targeting vegfa and methods for treatment in vivo |
WO2012047956A2 (en) | 2010-10-06 | 2012-04-12 | Opko Curna Llc | Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4 |
CN103180445B (en) | 2010-10-22 | 2018-02-16 | 库尔纳公司 | IDUA relevant diseases are treated by suppressing the natural antisense transcript of α L iduronases (IDUA) |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
JP6071893B2 (en) | 2010-11-23 | 2017-02-01 | カッパーアールエヌエー,インコーポレイテッド | Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG |
CN103620036B (en) | 2011-06-09 | 2016-12-21 | 库尔纳公司 | FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN) |
CN108272782B (en) | 2011-09-06 | 2021-04-23 | 库尔纳公司 | Use of small molecules in preparation of medicine for treating Dravet syndrome or generalized epilepsy with febrile convulsion adjunctive disease |
ES2694592T3 (en) | 2012-03-15 | 2018-12-21 | Curna, Inc. | Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of the natural antisense transcript of BDNF |
US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
WO2020109344A1 (en) | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Occular administration device for antisense oligonucleotides |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0874B2 (en) * | 1990-07-27 | 1996-01-10 | アイシス・ファーマシューティカルス・インコーポレーテッド | Nuclease-resistant, pyrimidine-modified oligonucleotides that detect and modulate gene expression |
EP1256589A3 (en) * | 1991-11-26 | 2003-09-17 | Isis Pharmaceuticals, Inc. | Oligomers containing modified pyrimidines |
US5484908A (en) * | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
US5731294A (en) * | 1993-07-27 | 1998-03-24 | Hybridon, Inc. | Inhibition of neovasularization using VEGF-specific oligonucleotides |
US6410322B1 (en) * | 1993-07-27 | 2002-06-25 | Hybridon Inc | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
US6150092A (en) * | 1994-06-27 | 2000-11-21 | Taogosei Company, Ltd. | Antisense nucleic acid compound targeted to VEGF |
DE19502912A1 (en) * | 1995-01-31 | 1996-08-01 | Hoechst Ag | G-Cap Stabilized Oligonucleotides |
-
1997
- 1997-04-17 EP EP97921238A patent/EP0910634A2/en not_active Withdrawn
- 1997-04-17 JP JP9537367A patent/JP2000509259A/en active Pending
- 1997-04-17 KR KR1019980708435A patent/KR20000005561A/en not_active Application Discontinuation
- 1997-04-17 AU AU27336/97A patent/AU2733697A/en not_active Abandoned
- 1997-04-17 CA CA002251945A patent/CA2251945A1/en not_active Abandoned
- 1997-04-17 BR BR9708701-7A patent/BR9708701A/en not_active Application Discontinuation
- 1997-04-17 WO PCT/US1997/006412 patent/WO1997039120A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0910634A2 (en) | 1999-04-28 |
CA2251945A1 (en) | 1997-10-23 |
BR9708701A (en) | 2000-01-04 |
KR20000005561A (en) | 2000-01-25 |
WO1997039120A2 (en) | 1997-10-23 |
WO1997039120A3 (en) | 1998-02-19 |
JP2000509259A (en) | 2000-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2733697A (en) | Antisense inhibitors of vascular endothelial growth factor (vegf/vpf) expression | |
HK1050032A1 (en) | Sputtering targets and method of making same | |
AU5439998A (en) | Vascular endothelial growth factor | |
AU2583399A (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf | |
AU3374795A (en) | Conjugates of vascular endothelial growth factor with targeted agents | |
NO960303D0 (en) | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression | |
AU4172397A (en) | Lactam inhibitors of thrombin | |
AU3640997A (en) | Iontophoretic delivery of integrin inhibitors | |
IL122186A (en) | Heterocycles as inhibitors of leucotype adhesion and as vla-4-antagonists | |
HUP9800634A3 (en) | P-amidino-benzylamide derivatives as thrombin inhibitors, intermediates and use thereof | |
PL330915A1 (en) | Phenylaniline derivatives as inhibitors of integrin | |
AU2002333623A1 (en) | Antisense modulation of vascular endothelial growth factor receptor-1 expression | |
PL331856A1 (en) | Heterocyclic inhibitors of metaloprotease | |
AU5023300A (en) | Vascular endothelial growth factor variants | |
PL331047A1 (en) | Novel amidinic derivatives and their application as inhibitors of thrombosin | |
AU2366295A (en) | Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation | |
AU4956500A (en) | Package for series of subpackages and method for shelving such subpackages | |
AU5599598A (en) | Inhibitors of glycosyltransferases | |
HUP9900979A3 (en) | Endothelial cell proliferation inhibitor and method of use | |
AU6253996A (en) | Inhibition of exoprotein in absorbent article | |
AU9312598A (en) | Inhibitors of collagen assembly | |
AU2277597A (en) | New inhibitors of sh2-mediated processes | |
AU4247097A (en) | Methods of making hiv-protease inhibitors and intermediates for making them | |
GB9509271D0 (en) | Blood clot stabilisation inhibitors | |
EP0758682A3 (en) | Hepatocyte growth factor activator inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted | ||
NB | Applications allowed - extensions of time section 223(2) |
Free format text: THE TIME IN WHICH TO OBTAIN ACCEPTANCE HAS BEEN EXTENDED TO 20010606 |
|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |